<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <!--The publisher of this article does not allow downloading of the full text in XML form.-->
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">JIMD Rep</journal-id>
      <journal-id journal-id-type="iso-abbrev">JIMD Rep</journal-id>
      <journal-title-group>
        <journal-title>JIMD Reports</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2192-8304</issn>
      <issn pub-type="epub">2192-8312</issn>
      <publisher>
        <publisher-name>Springer Berlin Heidelberg</publisher-name>
        <publisher-loc>Berlin, Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25822820</article-id>
      <article-id pub-id-type="pmc">4484907</article-id>
      <article-id pub-id-type="publisher-id">422</article-id>
      <article-id pub-id-type="doi">10.1007/8904_2015_422</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Effect and Tolerability of Agalsidase Alfa in Patients with Fabry Disease Who Were Treatment Naïve or Formerly Treated with Agalsidase Beta or Agalsidase Alfa</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Goker-Alpan</surname>
            <given-names>Ozlem</given-names>
          </name>
          <address>
            <email>ogokeralpan@oandoalpan.com</email>
          </address>
          <xref ref-type="aff" rid="Aff8"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nedd</surname>
            <given-names>Khan</given-names>
          </name>
          <xref ref-type="aff" rid="Aff9"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shankar</surname>
            <given-names>Suma P.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff10"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lien</surname>
            <given-names>Yeong-Hau H.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff11"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Weinreb</surname>
            <given-names>Neal</given-names>
          </name>
          <xref ref-type="aff" rid="Aff12"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wijatyk</surname>
            <given-names>Anna</given-names>
          </name>
          <xref ref-type="aff" rid="Aff13"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chang</surname>
            <given-names>Peter</given-names>
          </name>
          <xref ref-type="aff" rid="Aff14"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Martin</surname>
            <given-names>Rick</given-names>
          </name>
          <xref ref-type="aff" rid="Aff15"/>
        </contrib>
        <aff id="Aff8"><label/>Lysosomal Disorders Unit, O&amp;O ALPAN LLC, Fairfax, VA USA </aff>
        <aff id="Aff9"><label/>Infusion Associates, Grand Rapids, MI USA </aff>
        <aff id="Aff10"><label/>Department of Human Genetics and Ophthalmology, School of Medicine, Emory University, Atlanta, GA USA </aff>
        <aff id="Aff11"><label/>Arizona Kidney Disease and Hypertension Center, Tucson, AZ USA </aff>
        <aff id="Aff12"><label/>University Gaucher Disease–Fabry Disease Treatment Center, University Research Foundation for Lysosomal Storage Disorders, Coral Springs, FL USA </aff>
        <aff id="Aff13"><label/>Global Clinical Development, Shire, Lexington, MA USA </aff>
        <aff id="Aff14"><label/>Biometrics, Shire, Lexington, MA USA </aff>
        <aff id="Aff15"><label/>Global Medical, Shire, Lexington, MA USA </aff>
      </contrib-group>
      <contrib-group content-type="collaborators">
        <contrib contrib-type="Editor-in-chief">
          <name>
            <surname>Zschocke</surname>
            <given-names>Johannes</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1">Innsbruck, Austria </aff>
      </contrib-group>
      <author-notes>
        <fn fn-type="com">
          <p>Communicated by: Markus Ries, MD, PhD, MHSc, FCP</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>31</day>
        <month>3</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2015</year>
      </pub-date>
      <volume>23</volume>
      <fpage>7</fpage>
      <lpage>15</lpage>
      <history>
        <date date-type="received">
          <day>01</day>
          <month>10</month>
          <year>2014</year>
        </date>
        <date date-type="rev-recd">
          <day>22</day>
          <month>01</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>12</day>
          <month>02</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© SSIEM and Springer-Verlag Berlin Heidelberg 2015</copyright-statement>
      </permissions>
      <abstract id="Abs1">
        <p><italic>Objectives</italic>: In a multicenter, open-label, treatment protocol (HGT-REP-059; NCT01031173), clinical effects and tolerability of agalsidase alfa (agalα; 0.2 mg/kg every other week) were evaluated in patients with Fabry disease who were treatment naïve or switched from agalsidase beta (switch). Over 24 months, data were collected on the safety profile; renal and cardiac parameters were assessed using estimated glomerular filtration rate (eGFR), left ventricular mass index (LVMI), and midwall fractional shortening (MFS).</p>
        <p><italic>Results</italic>: Enrolled patients included 71 switch (median [range] age, 46.6 [5–84] years; male to female [M:F], 40:31) and 29 treatment naïve (38.7 [12–74] years; M:F, 14:15). Adverse events (AEs) were consistent with the known safety profile of agalα. Two switch patients had hospitalization due to possibly/probably drug-related serious AEs (one with transient ischemic attack, one with infusion-related AEs). One switch and two treatment-naïve patients discontinued treatment because of AEs. Three patients (one each switch, treatment naïve, and previous agalα) died; no deaths were considered drug-related. There was no significant change from baseline in LVMI or MFS in either group. Similarly, eGFR remained stable; mean ± standard error annualized change in eGFR (mL/min/1.73 m<sup>2</sup>) was −2.40 ± 1.04 in switch and −1.68 ± 2.21 in treatment-naïve patients.</p>
        <p><italic>Conclusions</italic>: This is the largest cohort of patients with Fabry disease who were started on or switched to agalα in an FDA-accepted protocol during a worldwide supply shortage of agalsidase beta. Because this protocol was primarily designed to provide access to agalα, there were limitations, including not having stringent selection criteria and the lack of a placebo group.</p>
      </abstract>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>© SSIEM and Springer-Verlag Berlin Heidelberg 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
</article>

